10.5 Multiple Sclerosis & Neuromuscular Junction Disorders
Key Takeaways
- Multiple sclerosis and other demyelinating diseases is a named subsection, as is diseases of muscle and neuromuscular junction.
- Multiple sclerosis requires dissemination in space and time, demonstrated clinically or by magnetic resonance imaging with oligoclonal bands.
- Myasthenia gravis worsens with sustained effort, whereas Lambert-Eaton syndrome improves with repeated activity and is associated with small cell lung cancer.
- Natalizumab carries a risk of progressive multifocal leukoencephalopathy that is stratified by JC virus antibody status, prior immunosuppression and treatment duration.
- Thymoma should be excluded by chest imaging in every patient with newly diagnosed myasthenia gravis.
Neuromuscular and demyelinating disorders encompass an array of autoimmune, paraneoplastic, and neurodegenerative conditions that frequently present with acute or subacute weakness, sensory disturbances, and respiratory failure. Differentiating central demyelination, neuromuscular junction transmission failure, lower motor neuron anterior horn cell loss, and peripheral polyradiculoneuropathies requires meticulous attention to clinical presentation, electrodiagnostics, and serological biomarkers.
1. Multiple Sclerosis (MS) & CNS Demyelinating Diseases
Multiple sclerosis is a chronic autoimmune, inflammatory, demyelinating disease of the central nervous system (CNS) characterized by autoreactive T cells and B cells crossing the blood-brain barrier and causing destruction of myelin sheaths, oligodendrocyte loss, axonal transection, and astrocytic gliosis.
Clinical Phenotypes
- Relapsing-Remitting MS (RRMS - ~85% of cases): Discrete, clearly defined acute attacks (relapses) with full or partial recovery, with no disease progression between relapses.
- Secondary Progressive MS (SPMS): Initial relapsing-remitting course followed by gradual, continuous neurological decline with or without occasional relapses or plateaus.
- Primary Progressive MS (PPMS - ~15% of cases): Insidious, continuous progression of neurological disability from disease onset without distinct initial relapses (frequently presenting as progressive spastic paraparesis in patients >40 years).
Classic Clinical Manifestations
- Optic Neuritis: Acute or subacute painful monocular vision loss (orbital pain exacerbated by eye movements), decreased visual acuity, central scotoma, impaired color vision (dyschromatopsia, especially red desaturation), and a Relative Afferent Pupillary Defect (RAPD / Marcus Gunn pupil). Funduscopy is normal in ~65% (retrobulbar neuritis) or reveals mild papillitis.
- Internuclear Ophthalmoplegia (INO): Demyelinating lesion involving the Medial Longitudinal Fasciculus (MLF) in the dorsomedial brainstem tegmentum, disrupting coordinated conjugate horizontal gaze:
- On attempted lateral gaze away from the lesion: Impaired adduction of the ipsilateral eye accompanied by dissociated horizontal nystagmus of the contralateral abducting eye.
- Convergence is preserved (mediated by a separate pathway through the pretectal nucleus).
- Board Rule: Bilateral INO in a young adult is virtually pathognomonic for Multiple Sclerosis.
- Lhermitte Sign: An electric shock-like sensation radiating down the spine and into the limbs triggered by passive or active neck flexion; signifies demyelinating plaques in the cervical posterior columns.
- Uhthoff Phenomenon: Transient worsening of pre-existing neurological deficits (e.g., visual blurring, weakness, paresthesias) triggered by increased core body temperature (hot shower, strenuous exercise, fever) due to conduction block across demyelinated axons.
- Transverse Myelitis & Spinal Cord Syndromes: Partial, asymmetric sensory levels, spastic paraparesis, and neurogenic bladder (detrusor hyperreflexia causing urinary urgency and urge incontinence).
Diagnostic Criteria & Workup (McDonald 2017 Criteria)
Diagnosis requires objective demonstration of CNS lesions Disseminated in Space (DIS) and Disseminated in Time (DIT):
- Dissemination in Space (DIS): >=1 T2-hyperintense lesions in >=2 of 4 typical CNS regions: (1) Periventricular (perpendicular ovoid lesions along medullary venules = "Dawson's fingers"); (2) Juxtacortical / Cortical; (3) Infratentorial (brainstem, cerebellum); (4) Spinal cord.
- Dissemination in Time (DIT): Simultaneous presence of asymptomatic gadolinium-enhancing and non-enhancing lesions on baseline MRI; or a new T2/enhancing lesion on follow-up MRI; or a second clinical attack; or the presence of CSF-specific oligoclonal bands (OCBs) in patients meeting DIS criteria.
- Lumbar Puncture (CSF Analysis): Demonstrates >=2 CSF-specific oligoclonal IgG bands absent in matched serum and an elevated CSF IgG Index (>0.7) with normal or minimally elevated total protein (<100 mg/dL) and mild lymphocytic pleocytosis (<50 cells/mcL).
Management of Multiple Sclerosis
- Acute Relapse Management:
- High-Dose IV Methylprednisolone: 1000 mg IV daily for 3 to 5 consecutive days (or equivalent high-dose oral prednisone 1250 mg daily) to accelerate recovery from acute functional impairment.
- Plasma Exchange (PEX): Indicated for severe, disabling steroid-refractory acute demyelinating relapses.
- Disease-Modifying Therapies (DMTs):
| DMT Drug Class | Specific Agents | Mechanism of Action | High-Yield Clinical Pearls & Toxicities |
|---|---|---|---|
| Monoclonal Antibody: Anti-Alpha-4 Integrin | Natalizumab (Tysabri) | Blocks alpha-4-beta-1 integrin (VLA-4) on lymphocytes, preventing endothelial adhesion and CNS transmigration | Highly effective (~68% relapse reduction). Black Box Warning: Progressive Multifocal Leukoencephalopathy (PML) caused by JC Virus (JCV) reactivation. Mandatory screening: Serum anti-JCV antibody testing every 6 months |
| Monoclonal Antibody: Anti-CD20 | Ocrelizumab (Ocrevus), Ofatumumab (Kesimpta), Ublituximab (Briumvi) | Depletes CD20+ B lymphocytes via antibody-dependent cell-mediated cytotoxicity | Ocrelizumab is FDA-approved for BOTH Relapsing MS and Primary Progressive MS (PPMS). Pre-treatment screening: Hepatitis B serologies (HBsAg, anti-HBc) and QuantiFERON-TB |
| Oral S1P Receptor Modulators | Fingolimod (Gilenya), Siponimod, Ozanimod, Ponesimod | Binds sphingosine-1-phosphate receptors, sequestering lymphocytes within lymph nodes | First-dose bradycardia / AV block (requires 6-hour baseline ECG monitoring for fingolimod); macular edema (baseline/follow-up ophthalmologic exams); VZV reactivation; PML |
| Platform Injectables | Interferon-beta-1a/1b, Glatiramer Acetate (Copaxone) | Immunomodulation / decoy myelin basic protein | Moderate efficacy. Glatiramer acetate is the preferred first-line agent during pregnancy and breastfeeding |
2. Neuromuscular Junction (NMJ) Disorders: Myasthenia Gravis vs LEMS
Disorders of the neuromuscular junction disrupt transmission between the motor nerve terminal and the skeletal muscle fiber, presenting with painless fatiguable or exercise-responsive weakness without sensory loss.
Clinical and Diagnostic Comparison of MG and LEMS
| Diagnostic Feature | Myasthenia Gravis (MG) | Lambert-Eaton Myasthenic Syndrome (LEMS) |
|---|---|---|
| Autoantibody Target & Site | Post-synaptic Acetylcholine Receptors (AChR-Ab in 85%) or Muscle-Specific Kinase (MuSK-Ab in 5-10%) | Pre-synaptic P/Q-type Voltage-Gated Calcium Channels (VGCC-Ab in >90%) |
| Mechanism of Failure | Complement-mediated destruction and endocytosis of AChR, flattening junctional folds | Impaired presynaptic calcium influx, blocking exocytosis of acetylcholine vesicles |
| Clinical Weakness Pattern | Fluctuating, fatiguable weakness: Ptosis, binocular diplopia (ocular MG in 50% at onset); bulbar weakness (dysphagia, nasal dysarthria, jaw fatigue); proximal limb weakness; worsens with activity and toward the end of the day | Proximal leg weakness (pelvic girdle: difficulty standing from a chair, climbing stairs); arms affected later; ocular/bulbar weakness is minimal or absent |
| Deep Tendon Reflexes | Normal (preserved) throughout | Absent or markedly diminished (hyporeflexia/areflexia) at rest |
| Autonomic Symptoms | Absent | Prominent: Dry mouth (xerostomia >80%), erectile dysfunction, constipation, orthostatic hypotension |
| Response to Exercise | Fatigues / Worsens with sustained or repetitive muscle contraction | Post-Exercise Facilitation: Muscle strength and deep tendon reflexes IMPROVE immediately after 10-15 seconds of maximal isometric muscle contraction |
| Bedside Tests | Ice Pack Test Positive: Application of ice pack to ptotic eyelid for 2-5 min improves ptosis by >=2 mm | Post-exercise reflex reappearance |
| Repetitive Nerve Stimulation (RNS) | Decremental Response (>10% drop in CMAP amplitude at 2-3 Hz low-frequency stimulation) | Incremental Response (>100% increase in CMAP amplitude at 20-50 Hz high-frequency stimulation or post-exercise) |
| Oncologic / Organ Association | Thymic Hyperplasia (65-70%) and Thymoma (10-15%) -> Mandatory contrast-enhanced Chest CT or MRI | Small Cell Lung Cancer (SCLC in 50-60%) -> Mandatory Chest CT with contrast / Whole-body PET-CT |
| First-Line Pharmacotherapy | Pyridostigmine (oral acetylcholinesterase inhibitor 30-60 mg q4-6h); Corticosteroids; Thymectomy | Amifampridine (3,4-diaminopyridine / 3,4-DAP); Definitive treatment of underlying small cell lung cancer |
Myasthenic Crisis & Management
- Definition: Life-threatening acute respiratory failure resulting from severe diaphragm and intercostal muscle weakness, often accompanied by severe bulbar weakness causing upper airway collapse and aspiration.
- Bedside Pulmonary Mechanics Monitoring (The 20/30/40 Rule):
- Forced Vital Capacity (FVC): Normal is 50-60 mL/kg. FVC < 15 to 20 mL/kg mandates elective endotracheal intubation.
- Negative Inspiratory Force (NIF): Normal is -70 to -100 cm H2O. NIF worse than -20 to -30 cm H2O (closer to zero) mandates elective intubation.
- Critical Board Warning: Never rely on pulse oximetry or arterial blood gas (ABG) analysis; hypoxemia and hypercapnia are dangerously late manifestations of impending diaphragmatic fatigue and respiratory arrest.
- Precipitating Factors & Contraindicated Medications:
- Triggers: Systemic infection (most common), surgery, pregnancy, tapering of immunosuppression.
- Strictly Contraindicated / Crisis-Inducing Medications:
- Antibiotics: Aminoglycosides (Gentamicin, Tobramycin), Fluoroquinolones (Ciprofloxacin, Levofloxacin), Macrolides (Azithromycin, Clarithromycin), Telithromycin.
- Neuromuscular / Electrolytes: Magnesium Sulfate (inhibits presynaptic ACh release; strictly avoided in pre-eclampsia/eclampsia if MG is present).
- Cardiovascular: Beta-blockers, Calcium channel blockers, Procainamide, Quinidine.
- Emergency Treatment of Crisis:
- Intravenous Immunoglobulin (IVIG: 2 g/kg total dose over 2 to 5 days) OR Plasma Exchange (PEX: 5 exchanges over 10-14 days). Both have equal high efficacy in restoring neuromuscular function within 3-7 days.
- Initiate or augment Corticosteroids (IV Methylprednisolone or oral Prednisone).
- Note: Pyridostigmine is temporarily held or reduced during mechanical ventilation to avoid excessive bronchorrhea and airway secretions.
Indications for Thymectomy in Myasthenia Gravis (MGTX Trial)
- Mandatory in ALL patients with Thymoma (regardless of age, antibody status, or severity of weakness).
- Indicated in non-thymomatous generalized AChR-antibody positive MG in patients aged 18 to 65 years to increase clinical remission rates, improve muscular strength, and significantly reduce long-term corticosteroid and immunosuppressant requirements.
A 34-year-old woman with a 2-year history of relapsing-remitting multiple sclerosis presents to her neurologist for a treatment modification after experiencing two clinical relapses over the past 12 months while on subcutaneous interferon beta-1a. Brain MRI demonstrates four new T2-hyperintense periventricular lesions with gadolinium enhancement. You discuss escalating therapy to Natalizumab (anti-alpha-4 integrin monoclonal antibody). Which mandatory laboratory screening test must be performed prior to initiating Natalizumab and monitored every 6 months during therapy to assess the risk of Progressive Multifocal Leukoencephalopathy (PML)?
A 64-year-old man with a 45 pack-year smoking history presents with a 3-month history of progressive weakness in his thighs and hips, causing severe difficulty rising from chairs and climbing stairs. He also reports persistent dry mouth and erectile dysfunction. On examination, proximal hip flexion strength is 3+/5 and patellar and Achilles tendon reflexes are completely absent bilaterally at rest. However, after the patient performs 15 seconds of maximal voluntary isometric quadriceps contraction, his hip flexion strength improves to 5-/5 and patellar reflexes become easily elicitable (2+). Low-frequency repetitive nerve stimulation (3 Hz) reveals low baseline CMAP amplitudes, whereas high-frequency stimulation (20 Hz) demonstrates a 180% incremental increase in CMAP amplitude. What is the most critical next diagnostic step in this patient?